Company intelligence / Profile preview
Shenzhen Jinruijiye Biotechnology
Shenzhen, Guangdong Sheng, Chinajrfbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shenzhen Jinruijiye Biotechnology is a private Chinese biotech company focused on oncology, with its lead program JRF-103 in Phase 2 clinical trials for advanced malignant solid neoplasms. The drug targets multiple EGFR mutations and HER family receptors using a small molecule approach. No additional clinical results are publicly available as of June 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Shenzhen Jinruijiye Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Jinruijiye Biotechnology.